Serious illness insurance solution provider Further Group has partnered with Massive Bio to increase patient access to clinical trials.

Massive Bio’s platform uses artificial intelligence (AI) to match patients to appropriate trials based on their cancer diagnosis.

According to Madrid, Spain-headquartered Further Group, the partnership will streamline the triage process and ensure more cancer patients can access potential treatments.

Further Group says it partners with insurers and employers to increase the accessibility of precision medicine and the world’s leading hospitals to patients who have cancer and other complex illnesses.

Patient selection and recruitment is an ever-present challenge for clinical trials. Historically, it is a time-consuming process and uses a lot of resources. The ability to integrate AI into the recruitment process can expedite the identification of suitable cohorts and alert patients to suitable trials.

A February 2022 report by Phesi found that 19% of 12,000 analysed clinical trial cancer sites enrolled just one patient.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In June 2023, the Precision Cancer Consortium comprising AstraZeneca, Bayer, Eli Lilly, GSK, Janssen of Johnson & Johnson, Novartis, and Roche, selected Massive Bio to help identify potential cancer patients for clinical trials. The consortium stated it aims to make data-driven precision oncology the standard for helping accelerate treatment access for cancer patients.

There is also an increasing importance in increasing diversity and inclusion in clinical trials. Racial and ethnic minorities are underrepresented in clinical research, and the US Food and Drug Administration (FDA) is encouraging sponsors to take proactive measures to ensure equitable patient participation.

Massive Bio’s chief financial officer Toygun Onaran said: “Our partnership with Further Group is a significant milestone in our shared mission to make cancer care accessible worldwide. We are excited to leverage our AI technology to identify optimal clinical trial options, ensuring personalised treatments for patients globally.”